gutflix
GI learning, personalised

Summary

ECONOMIC BURDEN OF SUBOPTIMAL TREATMENT WITH CORTICOSTEROID OVERUSE FOR ULCERATIVE COLITIS

Damemarie Paul

UEG Week Copenhagen 2023 | Poster

IBD

October 15, 2023

In a US claims database study of 4004 ulcerative colitis patients treated with first-line conventional therapy, 45.5% overused corticosteroids (defined as continuous use >90 days or ≥2 episodes within one year), and these patients incurred significantly higher healthcare costs and resource utilization than those without corticosteroid overuse.

KEY POINTS

- Among patients with corticosteroid overuse, median time from first-line treatment initiation to overuse was 9.4 months, and these patients were less likely to receive mesalamine monotherapy as first-line therapy compared to those without overuse (28.1% vs 56.7%).
- During follow-up, patients with corticosteroid overuse had higher rates of inpatient admissions (24.6% vs 14.2%) and emergency room visits (59.0% vs 50.5%) compared to those without overuse.
- Mean per-patient-per-year medical costs during follow-up were $10,418 for patients with corticosteroid overuse versus $4,922 for those without (P<0.001), and mean drug costs were $9,951 versus $5,923 (P<0.001).
- The authors suggest that patients with ulcerative colitis treated with prolonged corticosteroid courses may benefit from early use of advanced therapies associated with corticosteroid-free remission, though this represents the authors' opinion rather than a study finding.

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/ed1a7bdc-743b-11ee-a5ef-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.